Cost-Effectiveness of Nivolumab vs. Docetaxel as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.2209
https://www.valueinhealthjournal.com/article/S1098-3015(16)33575-6/fulltext
Title :
Cost-Effectiveness of Nivolumab vs. Docetaxel as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33575-6&doi=10.1016/j.jval.2016.09.2209
First page :
A732
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2093